| Aj Pakpour

The FDA’s latest actions could have a major impact on compounding pharmacies, healthcare providers, and patients relying on compounded peptide therapies. But what does it actually mean? In this video, I break down the regulatory landscape, what may be changing, who could be affected, and what healthcare professionals should be watching as the peptide industry continues to evolve. This isn’t about fear or hype. It’s about understanding the business, compliance, and operational implications before reacting to headlines. If you’re involved in functional medicine, hormone optimization, medical weight loss, longevity, or compounding, this is a conversation you don’t want to miss.